Log in

Relevant bibliographies by topics / Neoadjuvant chemo / Journal articles

To see the other types of publications on this topic, follow the link: Neoadjuvant chemo.

Journal articles on the topic 'Neoadjuvant chemo'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Neoadjuvant chemo.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Baumann and Köchli. "Primary Systemic Treatment of Invasive Breast Cancer." Swiss Surgery 6, no. 3 (2000): 137–41. http://dx.doi.org/10.1024/1023-9332.6.3.137.

Full text

Abstract:

Die präoperative oder neoadjuvante Chemo- oder Hormontherapie stellt in der Behandlung des lokal fortgeschrittenen Mammakarzinoms eine neue Therapieoption dar. Klinische Studien konnten keinen Unterschied bezüglich des Gesamtüberlebens für Patientinnen zeigen, die mit der konventionellen postoperativen, adjuvanten Therapie und den Patientinnen, die neoadjuvant behandelt wurden. Jedoch wurde durch die präoperative Chemo- und Hormontherapie in vielen Fällen eine deutliche Tumorverkleinerung und damit eine brusterhaltende Therapie erreicht. Die neoadjuvante Chemotherapie ist somit auch ein gutes

APA, Harvard, Vancouver, ISO, and other styles

2

Chiu, Joanne W., Roland Leung, Vikki Tang, et al. "Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy." Postgraduate Medical Journal 95, no. 1121 (2019): 155–61. http://dx.doi.org/10.1136/postgradmedj-2018-135739.

Full text

Abstract:

BackgroundOver the last 10 years, there has been a major treatment revolution for early human epidermal growth factor receptor 2 (HER2)–positive breast cancer. We aimed to explore the outcome of different neoadjuvant chemotherapy in a tertiary breast cancer centre with early HER2-positive breast cancer as well as factors associated with pathological complete response (pCR) and recurrence-free survival (RFS). The pattern of recurrence was also studied.MethodsThis retrospective study analysed the outcome of neoadjuvant chemotherapy during the period 2005 to 2016 in a tertiary referral centre in

APA, Harvard, Vancouver, ISO, and other styles

3

Ghelani, Ghanshyam H., Roger Wong, Stephen L. Graziano, Jeffrey S. Ross, and Alina Basnet. "Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8075. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8075.

Full text

Abstract:

8075 Background: Resectable Stage II and III Non-small Cell Lung Cancer (NSCLC) are managed with surgery and perioperative systemic therapy [Chemo/Chemo-Immunotherapy (IO)]. However, there lacks a consensus in optimal selection between neoadjuvant and adjuvant approaches. Hence, it underscores the necessity to undertake a comparative survival outcome associated with systemic therapy in these distinct settings. Methods: We conducted an analysis, of individuals aged 18 and above diagnosed with stage II and stage III NSCLC between 2004 - 2020, using data from the National Cancer Database (NCDB).

APA, Harvard, Vancouver, ISO, and other styles

4

Téoule, Patrick, Jörg Trojan, Wolf Bechstein, and Guido Woeste. "Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer." Digestive Surgery 32, no. 4 (2015): 229–37. http://dx.doi.org/10.1159/000381884.

Full text

Abstract:

Background/Aims: Patients with locally advanced gastric cancer benefit from neoadjuvant chemotherapy. Potential disadvantages of neoadjuvant chemotherapy include increased surgical complications, leading to increased postoperative morbidity. Methods: We retrospectively studied medical records of 135 patients with resectable cancer of the stomach who underwent gastrectomy between 2002 and 2009. The impact of neoadjuvant chemotherapy on postoperative morbidity was investigated. We compared demographic, clinical and operative data, morbidity and mortality from 105 patients who received surgical t

APA, Harvard, Vancouver, ISO, and other styles

5

Siefker-Radtke, Arlene O., Gary D. Steinberg, Jens Bedke, et al. "Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866." Journal of Clinical Oncology 38, no. 6_suppl (2020): TPS599. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps599.

Full text

Abstract:

TPS599 Background: MIBC prognosis is poor, despite standard neoadjuvant cisplatin-based chemo. PD-1/PD-L1 pathway inhibition is an effective first-line option for cisplatin-ineligible pts and a second-line option for platinum-based chemo pretreated pts. Neoadjuvant chemo + pembro, a PD-1 inhibitor, recently showed encouraging pathologic complete response rates, in cisplatin-eligible patients with MIBC (NCT02365766), warranting further investigation. Methods: KEYNOTE-866 (NCT03924856) is a randomized phase 3 study to assess efficacy and safety of chemo+perioperative pembro versus chemo+perioper

APA, Harvard, Vancouver, ISO, and other styles

6

Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al. "Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816." Journal of Clinical Oncology 42, no. 17_suppl (2024): LBA8010. http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba8010.

Full text

Abstract:

LBA8010 Background: The phase 3 CheckMate 816 study established neoadjuvant NIVO + chemo as a standard of care for eligible pts with resectable NSCLC. Here, we report the 4-year survival update from this study, representing the longest follow-up among all global phase 3 studies evaluating neoadjuvant or perioperative immunotherapy-based treatments. Methods: Adults with stage IB (≥ 4 cm)–IIIA (per AJCC v7) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ ALK alterations were randomized 1:1 to receive NIVO 360 mg + chemo Q3W or chemo alone Q3W for 3 cycles, followed by surgery. Event-free survi

APA, Harvard, Vancouver, ISO, and other styles

7

Jiang, Bo, Xin Yang, Pengyi Yu, et al. "Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14626-e14626. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14626.

Full text

Abstract:

e14626 Background: More and more studies focus on the neoadjuvant chemotherapy combined with immunotherapy (chemo-immunotherapy) in resectable esophageal squamous carcinoma (ESCC). Herein, we aimed to evaluate the efficacy and safety of neoadjuvant programmed cell death protein 1 inhibitors with chemotherapy and explore tumor microenvironment (TME) profiles. Methods: Patients with previously untreated, resectable, stage III ESCC in the third affiliated hospital of Soochow University were enrolled. Each patient received two-four cycles of neoadjuvant chemo-immunotherapy before surgical resectio

APA, Harvard, Vancouver, ISO, and other styles

8

Chen, Yilin, Lu Yang, Yuhong Huang, et al. "Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer." Journal for ImmunoTherapy of Cancer 13, no. 4 (2025): e010365. https://doi.org/10.1136/jitc-2024-010365.

Full text

Abstract:

BackgroundNeoadjuvant immunotherapy combined with chemotherapy (Chemo-IM) is associated with significantly improved pathological complete response (pCR) rates and long-term survival outcomes in patient with early-stage triple-negative breast cancer (TNBC). However, only a small proportion of patients benefit from the addition of immunotherapy. Here, we explored and confirmed the role of intratumoral microbiota in screening patients with TNBC who are likely to benefit from neoadjuvant Chemo-IM.MethodsPatients with previously untreated, non-metastatic TNBC receiving neoadjuvant Chemo-IM were enr

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, Changli, Ke-Neng Chen, Qixun Chen, et al. "Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816." Cancer Research 83, no. 8_Supplement (2023): CT081. http://dx.doi.org/10.1158/1538-7445.am2023-ct081.

Full text

Abstract:

Abstract Background: In the global, randomized phase 3 CheckMate 816 study (NCT02998528), neoadjuvant NIVO + chemo demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) vs chemo in pts with resectable NSCLC. Here, we report results from the Chinese subgroup of this study. Methods: Adults with stage IB (≥ 4 cm)-IIIA (per AJCC 7th edition) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ALK mutations were randomized to NIVO 360 mg + chemo Q3W or chemo Q3W for 3 cycles followed by surgery. EFS and pCR (pe

APA, Harvard, Vancouver, ISO, and other styles

10

Malapati, Sindhu Janarthanam, Sunny R. K. Singh, Rohit Kumar, and Tarik H. Hadid. "Neoadjuvant treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer: Analysis of the National Cancer Database." Journal of Clinical Oncology 38, no. 15_suppl (2020): 7046. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.7046.

Full text

Abstract:

7046 Background: Use of neoadjuvant chemotherapy (Neo-chemo) improves survival in locally advanced NSCLC. However, data regarding the benefit of adding radiation (Neo-CRT) is limited. Meta-analyses suggest that the use of Neo-CRT could lead to significant tumor downstaging but with increase in therapy-related mortality. Methods: Patients with resected stage III NSCLC were identified from the NCDB between 2010 and 2015. Patients were divided into two groups based on the type of neoadjuvant therapy received (Neo-chemo vs. Neo-CRT). Surgical and survival outcomes were compared. Kaplan-Meier metho

APA, Harvard, Vancouver, ISO, and other styles

11

Hale, Matthew D., Matthew Guy Nankivell, Wolfram Mueller, et al. "The relationship between tumor cell density in the pretreatment biopsy and survival after chemotherapy in OE02 trial esophageal cancer patients." Journal of Clinical Oncology 32, no. 3_suppl (2014): 49. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.49.

Full text

Abstract:

49 Background: Neoadjuvant chemotherapy (chemo) followed by surgery is the standard treatment for UK patients with resectable oesophageal cancer [OeC] since the OE02 trial (Allum et al. J. Clin. Oncol, 2009), yet some patients receive no benefit from chemo. We investigated whether tumour cell density (TCD) in the pre-chemo biopsy can predict patient benefit from chemo among OE02 patients. Methods: Hematoxylin and eosin stained diagnostic biopsy slides from 281 OE02 trial OeC patients reflective of the whole trial population based on patient characteristics and survival (70% adenocarcinoma, sur

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Neoadjuvant chemo ?? radiotherapy in oesophageal cancer." Inpharma Weekly &NA;, no. 1584 (2007): 18. http://dx.doi.org/10.2165/00128413-200715840-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

West, Malcolm A., Zachos Anastasiou, Gareth Ambler, et al. "The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study." NIHR Open Research 1 (June 16, 2021): 1. http://dx.doi.org/10.3310/nihropenres.13217.1.

Full text

Abstract:

Background: Neoadjuvant cancer treatment is associated with improved survival following major oesophagogastric cancer surgery. The impact of neoadjuvant chemo/chemoradiotherapy on physical fitness and operative outcomes is however unclear. This study aims to investigate the impact of neoadjuvant chemo/chemoradiotherapy on fitness and post-operative mortality. Methods: Patients with oesophagogastric cancer scheduled for chemo/chemoradiotherapy and surgery were recruited to a prospective, blinded, multi-centre, observational cohort study. Primary outcomes were changes in fitness with chemo/chemo

APA, Harvard, Vancouver, ISO, and other styles

14

Spicer, Jonathan, Changli Wang, Fumihiro Tanaka, et al. "Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 8503. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.8503.

Full text

Abstract:

8503 Background: CheckMate 816 (NCT02998528) is a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo in resectable NSCLC. The study met its first primary endpoint, demonstrating significantly improved pathological complete response (pCR) with neoadjuvant NIVO + chemo. Here we report key surgical outcomes from the study. Methods: Adults with stage IB (≥ 4 cm)–IIIA (per AJCC 7th ed) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ ALK alterations were randomized to NIVO 360 mg + platinum-doublet chemo Q3W or chemo Q3W for 3 cycles (n = 179 each). Definitive surgery was to be performe

APA, Harvard, Vancouver, ISO, and other styles

15

Bajorin, Dean F., Johannes Alfred Witjes, Jürgen Gschwend, et al. "First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)." Journal of Clinical Oncology 39, no. 6_suppl (2021): 391. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.391.

Full text

Abstract:

391 Background: The standard of care (SOC) for patients (pts) with MIUC is radical surgery ± cisplatin-based neoadjuvant chemotherapy (chemo), but many pts are cisplatin-ineligible. There is no conclusive evidence supporting adjuvant chemo in pts who did not receive neoadjuvant chemo and in those with residual disease after neoadjuvant cisplatin. This phase 3 trial of adjuvant nivolumab (NIVO) vs placebo (PBO) in pts with MIUC after radical surgery ± neoadjuvant cisplatin (CheckMate 274) aims to address an unmet need in these pts. We report the initial results. Methods: This is a phase 3, rand

APA, Harvard, Vancouver, ISO, and other styles

16

Faehling, Martin, Hanno Witte, Martin Sebastian, et al. "Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)." Therapeutic Advances in Medical Oncology 14 (January 2022): 175883592210853. http://dx.doi.org/10.1177/17588359221085333.

Full text

Abstract:

Background: Recent clinical trials demonstrate the feasibility of neoadjuvant immuno(chemo)therapy and report high rates of pathological remission, a surrogate marker for overall survival. Patients and methods: This is a retrospective multicentre real-world analysis of patients with locally resectable NSCLC, including oligometastatic disease, who received neoadjuvant immuno(chemo)therapy and resection. Consolidating immunotherapy was applied following multidisciplinary board recommendation. Primary endpoint was the rate of complete pathological response (pCR, no residual vital tumour cells) or

APA, Harvard, Vancouver, ISO, and other styles

17

Girard, Nicolas, Jonathan Spicer, Mariano Provencio, et al. "Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial." Cancer Research 82, no. 12_Supplement (2022): CT012. http://dx.doi.org/10.1158/1538-7445.am2022-ct012.

Full text

Abstract:

Abstract Background: CheckMate 816 (NCT02998528), a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo for resectable NSCLC, met its first primary endpoint with a statistically significant improvement in pathological complete response (pCR) rate (24% vs 2%; odds ratio 13.94 [99% CI, 3.49-55.75; P &lt; 0.0001]). pCR benefit was consistent across key subgroups, including disease stages, histologies, and PD-L1 expression levels. Notably, neoadjuvant NIVO + chemo did not impede feasibility of surgery nor increase incidence of surgical complications or adverse events (AEs) vs chemo a

APA, Harvard, Vancouver, ISO, and other styles

18

Shao, Zhi-Ming, Li Chen, Hui Li, et al. "Abstract GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial." Clinical Cancer Research 31, no. 12_Supplement (2025): GS3–06—GS3–06. https://doi.org/10.1158/1557-3265.sabcs24-gs3-06.

Full text

Abstract:

Abstract Background: For early or locally advanced TNBC, preferred neoadjuvant strategies include a four-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Accumulating evidence suggests that blockade of the PD-1/PD-L1 pathway may enhance the efficacy of conventional neoadjuvant chemotherapy. Camrelizumab is an anti-PD-1 antibody that has demonstrated antitumor activity in advanced or metastatic TNBC. Herein, we conducted a double-blind, randomized phase 3 trial (NCT04613674) to evaluate the efficacy and safety of neoadjuvant camrelizumab plus chemo i

APA, Harvard, Vancouver, ISO, and other styles

19

Provencio, M., V. Calvo, R. Laza Briviesca, and A. Cruz-Bermudez. "ES06.01 Neoadjuvant IO Monotherapy vs. Chemo-IO." Journal of Thoracic Oncology 16, no. 3 (2021): S70—S71. http://dx.doi.org/10.1016/j.jtho.2021.01.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Neoadjuvant chemo in NSCLC not necessarily beneficial." Inpharma Weekly &NA;, no. 1591 (2007): 12. http://dx.doi.org/10.2165/00128413-200715910-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Yeung, Kai Tai Derek, Sacheen Kumar, David Cunningham, Long R. Jiao, and Ricky Harminder Bhogal. "Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma." Annals of Surgery Open 5, no. 3 (2024): e486. http://dx.doi.org/10.1097/as9.0000000000000486.

Full text

Abstract:

Objective: To assess overall survival (OS), compare the effects of neoadjuvant treatment, and describe surgical outcomes for patients undergoing pancreatic resection following chemotherapy and/or chemoradiotherapy (CRT) for borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Background: We approach BR/LA PDAC using chemotherapy followed by selective CRT to the primary site of disease where either the surgical margin remains radiologically threatened following chemotherapy or as a further downstaging treatment. Methods: Retrospective study of patients be

APA, Harvard, Vancouver, ISO, and other styles

22

Campian, Jian Li, Xiaobu Ye, Craig Hooker, Malcolm Brock, and Stuart A. Grossman. "Incidence, severity, and etiology of treatment-related lymphopenia in patients with stage III non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 30, no. 15_suppl (2012): e17552-e17552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e17552.

Full text

Abstract:

e17552 Background: Severe treatment-related lymphopenia (TRL) is associated with shorter survival in patients with glioblastoma and pancreatic cancer treated with concurrent chemotherapy and radiation (chemo/RT). This retrospective study sought to determine if patients with stage III NSCLC develop TRL and if this results from chemotherapy or radiation. Methods: Patients selected for this retrospective analysis had newly diagnosed stage III NSCLC, Karnofsky performance status >60, and chemo/RT and follow-up blood counts at Johns Hopkins Hospital. Patients were divided into those who received

APA, Harvard, Vancouver, ISO, and other styles

23

Li, Jia-yi, Xuan-zhang Huang, Peng Gao, et al. "Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment." BioMed Research International 2021 (March 27, 2021): 1–21. http://dx.doi.org/10.1155/2021/8852699.

Full text

Abstract:

Background. Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits. Methods. We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (

APA, Harvard, Vancouver, ISO, and other styles

24

Xiong, Liwen, Yuqing Lou, Hao Bai, et al. "Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients." Journal of International Medical Research 48, no. 4 (2019): 030006051988727. http://dx.doi.org/10.1177/0300060519887275.

Full text

Abstract:

Background The optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly improved survival in patients with EGFR-mutant advanced NSCLC. However, their efficacy in neoadjuvant settings, particularly for treating locally advanced NSCLC, remains unclear. We compared the clinical benefits of chemotherapy and erlotinib as neoadjuvant therapy for stage IIIA NSCLC. Method Thirty-one treatment-naïve Chinese patients with stage IIIA NSCLC were enrolled. Patients without EGFR mutation received cisplatin-based

APA, Harvard, Vancouver, ISO, and other styles

25

Franzi, Sara, Giovanni Mattioni, Erika Rijavec, Giorgio Alberto Croci, and Davide Tosi. "Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature." Journal of Clinical Medicine 11, no. 9 (2022): 2629. http://dx.doi.org/10.3390/jcm11092629.

Full text

Abstract:

Non-small cell lung cancer accounts for approximately 80–85% of all lung cancers and at present represents the main cause of cancer death among both men and women. To date, surgery represents the cornerstone; nevertheless, around 40% of completely resected patients develop disease recurrence. Therefore, combining neoadjuvant chemo-immunotherapy and surgery might lead to improved survival. Immunotherapy is normally well tolerated, although significant adverse reactions have been reported in certain patients treated with inhibitors of immune checkpoints. In this review, we explore the current li

APA, Harvard, Vancouver, ISO, and other styles

26

Willems, R. A. L., N. Michiels, V. R. Lanting, et al. "Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care." Cancers 15, no. 14 (2023): 3546. http://dx.doi.org/10.3390/cancers15143546.

Full text

Abstract:

Recent studies have shown that patients with pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemo(radio)therapy followed by surgery have an improved outcome compared to patients treated with upfront surgery. Hence, patients with PDAC are more and more frequently treated with chemotherapy in the neoadjuvant setting. PDAC patients are at a high risk of developing venous thromboembolism (VTE), which is associated with decreased survival rates. As patients with PDAC were historically offered immediate surgical resection, data on VTE incidence and associated preoperative risk fact

APA, Harvard, Vancouver, ISO, and other styles

27

Cascone, Tina, Mariano Provencio, Boris Sepesi, et al. "Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS9076. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps9076.

Full text

Abstract:

TPS9076 Background: Although surgery for early NSCLC is potentially curative, 5-year overall survival (OS) rates for patients with stage IIA–IIIB disease are historically < 50%, representing a population of high unmet need. Conventional neoadjuvant or adjuvant chemo provides only a 5% absolute improvement in OS at 5 years. A rational approach to improve survival in these patients is to eradicate micrometastatic disease and potentially induce anti-tumor immunity to minimize the risk of relapse with peri-operative regimens including NIVO, a fully human anti–programmed death receptor-1 antibod

APA, Harvard, Vancouver, ISO, and other styles

28

Castellanos, Raquel, Vinicius Ernani, Ulas Darda Bayraktar, et al. "A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC)." Journal of Clinical Oncology 31, no. 4_suppl (2013): 138. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.138.

Full text

Abstract:

138 Background: Perioperative chemotherapy (chemo) with ECF (epirubicin/cisplatin/5-fluorouracil) plus surgery improved survival over surgery alone in GC in the MAGIC trial. Herein we report our experience using DCF in the perioperative setting in patients (pts) with locally advanced GC. Methods: We conducted a retrospective IRB-approved study of pts with potentially resectable locally advanced GC who were treated with DCF with neoadjuvant intent. Pts received 3 cycles of preoperative (pre-op) DCF every 3 weeks, followed by surgery, then 3 cycles of postoperative (post-op) DCF. Patients with a

APA, Harvard, Vancouver, ISO, and other styles

29

Mc Laughlin, Ronan Andrew, Majid Almeraikhi, Humaid Alkaabi, et al. "Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity." Journal of Clinical Oncology 41, no. 4_suppl (2023): 335. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.335.

Full text

Abstract:

335 Background: In locally advanced esophageal cancer, neoadjuvant chemo-radiotherapy improves survival compared with surgery alone. In the Chemo-Radiotherapy for Oesophageal cancer followed by Surgery Study (CROSS), the median age was 60. However, 1/3 of patients diagnosed with esophageal cancer are over 70 years. The CROSS outcomes are therefore limited in its application to older patients. The objective of this study is to report and compare the outcomes and tolerability in elderly patients (≥70 years), who underwent neoadjuvant chemo-radiation for esophageal cancer with younger patients &l

APA, Harvard, Vancouver, ISO, and other styles

30

Schmid, Peter, Javier Cortés, Rebecca Dent, et al. "Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study." Cancer Research 84, no. 9_Supplement (2024): LBO1–01—LBO1–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-lbo1-01.

Full text

Abstract:

Abstract Background: In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) followed by adjuvant pembro showed statistically significant and clinically meaningful improvements in pathological complete response (pCR) and event-free survival (EFS) compared with neoadjuvant placebo (pbo) plus chemo followed by adjuvant pbo in patients (pts) with early-stage triple-negative breast cancer (TNBC). Here, we present updated EFS results after a median follow-up of ~5 y. Methods: Eligible pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T

APA, Harvard, Vancouver, ISO, and other styles

31

Wang, Xiao, Sharyn I. Katz, Leonid Roshkovan, et al. "A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma." Journal of Clinical Oncology 38, no. 15_suppl (2020): e21093-e21093. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e21093.

Full text

Abstract:

e21093 Background: Malignant peritoneal mesothelioma (MPM) is a rare variant of malignant mesothelioma, representing < 30% of cases. Standard of care is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) when feasible. The benefit of systemic chemotherapy (chemo) (Neoadjuvant- N, Adjuvant- A, or 1st-line metastatic –M) is not well established and some retrospective studies report worse outcomes with N chemo. However, our institution has favored use of N chemo prior to surgery for symptom relief and surgical optimization. We conducted a single-center retrospec

APA, Harvard, Vancouver, ISO, and other styles

32

Banna, Giuseppe Luigi, Mona Ali Hassan, Alessio Signori, et al. "Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer." JAMA Network Open 7, no. 4 (2024): e246837. http://dx.doi.org/10.1001/jamanetworkopen.2024.6837.

Full text

Abstract:

ImportanceRandomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non–small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data.ObjectiveTo assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors.Data SourcesFull-text articles and abstracts in English we

APA, Harvard, Vancouver, ISO, and other styles

33

Carlson, Robert H. "Neoadjuvant Chemo-RT Response Rates May Outweigh Risks." Oncology Times 25, no. 13 (2003): 60–61. http://dx.doi.org/10.1097/01.cot.0000290857.80071.be.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

MCNAMARA, DAMIAN. "Wider Role for Neoadjuvant Chemo in Ovarian Cancer." Ob.Gyn. News 46, no. 5 (2011): 32. http://dx.doi.org/10.1016/s0029-7437(11)70156-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Trabalza Marinucci, Beatrice, Massimiliano Mancini, Alessandra Siciliani, et al. "Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature." Cancers 17, no. 4 (2025): 638. https://doi.org/10.3390/cancers17040638.

Full text

Abstract:

Non-small-cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers. Approximately 20% of patients with NSCLC are diagnosed with stage IIIA–IIIB disease, for which the optimal treatment remains unclear. Meta-analyses reveal that neoadjuvant/perioperative ICI–chemotherapy significantly improves pathological complete response (pCR), overall survival (OS), major pathological response (MPR), and R0 rate compared to standard neoadjuvant chemotherapy. Resectability is achieved when R0 resection can be performed after surgery. Radiographic downstaging often does not correspond to surgical down

APA, Harvard, Vancouver, ISO, and other styles

36

Pastori, Chiara, Ebtesam H. O. Nafie, Mukta S. Wagh, Stephen J. Hunt, and Robert E. Neal. "Neoadjuvant chemo-immunotherapy is improved with a novel pulsed electric field technology in an immune-cold murine model." PLOS ONE 19, no. 3 (2024): e0299499. http://dx.doi.org/10.1371/journal.pone.0299499.

Full text

Abstract:

Chemo-immunotherapy uses combined systemic therapies for resectable and unresectable tumors. This approach is gaining clinical momentum, but survival increases leave considerable room for improvement. A novel form of Pulsed Electric Field (PEF) ablation combines focal tissue destruction with immune activation in preclinical settings. The PEFs induce lethal cell damage without requiring thermal processes, leaving cellular proteins intact. This affords PEF a favorable safety profile, improved antigenicity, and significant immunostimulatory damage-associated molecular pattern release compared to

APA, Harvard, Vancouver, ISO, and other styles

37

Ng, Camille, Sungjin Kim, Michelle Guan, et al. "The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): e16564-e16564. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16564.

Full text

Abstract:

e16564 Background: In rGC ( > cT2), we investigated the impact of various neoadjuvant and/or adjuvant treatment modalities on pathologic complete response (pCR), surgical margins, and overall survival (OS). Methods: The National Cancer Database (NCDB) was interrogated to identify rGC patients (pts) between 2004-2015. Gastric adenocarcinoma cases that were cT2-T4b, any N, M0 and underwent definitive surgery were included. We analyzed the association of 9 treatment groups: neoadjuvant chemoradiation only (nCRT), neoadjuvant chemo only (nCT), adjuvant chemo only (aCT), adjuvant chemoradiation

APA, Harvard, Vancouver, ISO, and other styles

38

Hav, Monirath, Louis Libbrecht, Liesbeth Ferdinande, Karen Geboes, Piet Pattyn, and Claude A. Cuvelier. "Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications." BioMed Research International 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/574540.

Full text

Abstract:

Neoadjuvant radio(chemo)therapy is increasingly used in rectal cancer and induces a number of morphologic changes that affect prognostication after curative surgery, thereby creating new challenges for surgical pathologists, particularly in evaluating morphologic changes and tumour response to preoperative treatment. Surgical pathologists play an important role in determining the many facets of rectal carcinoma patient care after neoadjuvant treatment. These range from proper handling of macroscopic specimens to accurate microscopic evaluation of pathological features associated with patients’

APA, Harvard, Vancouver, ISO, and other styles

39

Bhandari, T. "The role of panendoscopy in the staging of high risk head & neck squamous cell carcinoma prior to therapy: Is it of value?" Journal of Clinical Oncology 24, no. 18_suppl (2006): 5569. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5569.

Full text

Abstract:

5569 Background: Panendoscopy (triple endoscopy) has historically been advocated to adequately stage patients w/ head & neck squamous cancer, especially in the setting of neoadjuvant therapy. This role is controversial by in view of comparable information provided by current imaging techniques Objective: The primary objective was to analyze the results of panendoscopy in a series of patients enrolled in a neoadjuvant chemo radiation protocol. Methods: We reviewed the panendoscopy results of 69 pts w/ stage III/IV head & neck squamous cell carcinoma (H&N ca) treated w/ neoadjuvant c

APA, Harvard, Vancouver, ISO, and other styles

40

Stefani, Dirk, Till Plönes, Jan Viehof, et al. "Lung Cancer Surgery after Neoadjuvant Immunotherapy." Cancers 13, no. 16 (2021): 4033. http://dx.doi.org/10.3390/cancers13164033.

Full text

Abstract:

In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates rema

APA, Harvard, Vancouver, ISO, and other styles

41

H.G, Vinay, and Vybhav R. "The Outcome of Neoadjuvant Chemo Radiotherapy and Surgery in Carcinoma Rectum: Our Experience." New Indian Journal of Surgery 9, no. 1 (2018): 97–102. http://dx.doi.org/10.21088/nijs.0976.4747.9118.19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Bohle, Wolfram, Ioannis Louris, Andre Schaudt, Joerg Koeninger, and Wolfram G. Zoller. "Predictors for Treatment Failure of Self-Expandable Metal Stents for Anastomotic Leak after Gastro-Esophageal Resection." Journal of Gastrointestinal and Liver Diseases 29, no. 2 (2020): 145–49. http://dx.doi.org/10.15403/jgld-463.

Full text

Abstract:

Background and Aims: Self-expandable metal stents are used for the treatment of anastomotic leaks after gastro- esophageal surgery. Predictors for treatment failure and complications are unknown. In this observational retrospective study, we summarize our experience with self-expandable metal stents for the treatment of anastomotic leaks, in order to determine the predictors of treatment failure. Methods: Between 2009 and 2015, 34 patients with anastomotic leak after curative resection of gastro- esophageal cancer were treated with self-expandable metal stents. Gender, histology, comorbi

APA, Harvard, Vancouver, ISO, and other styles

43

Miriyala, Raviteja, Umesh Mahantshetty, Amita Maheshwari, and Sudeep Gupta. "Neoadjuvant chemotherapy followed by surgery in cervical cancer: past, present and future." International Journal of Gynecologic Cancer 32, no. 3 (2022): 260–65. http://dx.doi.org/10.1136/ijgc-2021-002531.

Full text

Abstract:

BackgroundCisplatin-based concurrent chemoradiation is the standard treatment for locally advanced cervical cancer. In view of the difficulties associated with implementation of standard radiation protocols in low- and middle-income countries and the associated toxicities of chemoradiation, neoadjuvant chemotherapy followed by surgery has been tried as an alternative treatment for locally advanced cervical cancer.MethodsA comprehensive review was undertaken of the existing literature, caveats and potential avenues of neoadjuvant chemotherapy followed by surgery compared with chemoradiation in

APA, Harvard, Vancouver, ISO, and other styles

44

Ogura, Atsushi, Stefan van Oostendorp, and Miranda Kusters. "Neoadjuvant (chemo)radiotherapy and Lateral Node Dissection: Is It Mutually Exclusive?" Clinics in Colon and Rectal Surgery 33, no. 06 (2020): 355–60. http://dx.doi.org/10.1055/s-0040-1714239.

Full text

Abstract:

AbstractThe importance of total mesorectal excision (TME) has been the global standard of care in patients with rectal cancer. However, there is no universal strategy for lateral lymph nodes (LLN). The treatment of the lateral compartment remains controversial and has gone to the opposite directions between Eastern and Western countries in the past decades. In the East, mainly Japan, surgeons consider LLN metastases as regional disease and have performed TME with lateral lymph node dissection (LLND) without neoadjuvant (chemo)radiotherapy ([C]RT) in patients with clinical Stage II/III rectal c

APA, Harvard, Vancouver, ISO, and other styles

45

Verma, Saurav, Mark David Vincent, Morgan Black, et al. "Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study." Journal of Clinical Oncology 42, no. 16_suppl (2024): e20077-e20077. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e20077.

Full text

Abstract:

e20077 Background: Neoadjuvant (NA) nivolumab-chemotherapy (nivo-chemo) has shown an improved survival and pathological complete response (pCR) rate, vs chemo alone, in early-stage, resectable non-small cell lung cancer (NSCLC). Nevertheless, there is a paucity of real-world data. Methods: We performed a real-world, retrospective analysis of outcomes and toxicities in patients with resectable NSCLC (stage IB-IIIA; EGFR/ALK alterations excluded) treated with three cycles of NA nivo-chemo followed by surgery at a single, tertiary-level Canadian cancer centre from September 2022 to September 2023

APA, Harvard, Vancouver, ISO, and other styles

46

Zhang, Yongchang, Liang Zeng, Xiangyu Zhang, et al. "The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer." Journal of Clinical Oncology 39, no. 15_suppl (2021): e20526-e20526. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e20526.

Full text

Abstract:

e20526 Background: Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced non-small cell lung cancer (NSCLC). However, its application in neoadjuvant scenario has not been well established. Here, we conducted a retrospective study to evaluate the efficacy and safety of neoadjuvant chemo-immunotherapy for patients with potentially resectable NSCLC. Methods: We retrospectively reviewed clinical records of patients with potentially resectable NSCLC (stage IIIA-IIIB) with non-driver gene mutation. The patients underwent neoadjuvant

APA, Harvard, Vancouver, ISO, and other styles

47

Wang, X., M. Fang, Y. Jiang, K. Tao, and Y. Ji. "406P Neoadjuvant chemo-immunotherapy versus neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma." Annals of Oncology 35 (June 2024): S165. http://dx.doi.org/10.1016/j.annonc.2024.05.320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Susman, Ed. "Neoadjuvant Chemo Allows for Surgery in ‘Inoperable’ Esophageal Cancer." Oncology Times 26, no. 4 (2004): 8–11. http://dx.doi.org/10.1097/01.cot.0000291230.61028.bb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Greto, D., M. Loi, M. Banini, et al. "Neoadjuvant (Chemo-) Radiotherapy for Locally Advanced Soft Tissue Sarcoma." International Journal of Radiation Oncology*Biology*Physics 120, no. 2 (2024): e446. http://dx.doi.org/10.1016/j.ijrobp.2024.07.992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Fietkau, Rainer. "Rectal cancer: quo vadis, neoadjuvant and adjuvant (chemo) radiotherapy?" International Journal of Colorectal Disease 25, no. 2 (2009): 285–87. http://dx.doi.org/10.1007/s00384-009-0825-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!